Search results
Showing 1 to 9 of 9 results for belantamab mafodotin
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
In development Reference number: GID-TA10979 Expected publication date: TBC
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
Discontinued Reference number: GID-TA10568
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Discontinued Reference number: GID-TA11018
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.